Skip to main content
Journal cover image

New advances in focal therapy for early stage prostate cancer.

Publication ,  Journal Article
Tay, KJ; Schulman, AA; Sze, C; Tsivian, E; Polascik, TJ
Published in: Expert Rev Anticancer Ther
August 2017

Prostate focal therapy offers men the opportunity to achieve oncological control while preserving sexual and urinary function. The prerequisites for successful focal therapy are to accurately identify, localize and completely ablate the clinically significant cancer(s) within the prostate. We aim to evaluate the evidence for current and upcoming technologies that could shape the future of prostate cancer focal therapy in the next five years. Areas covered: Current literature on advances in patient selection using imaging, biopsy and biomarkers, ablation techniques and adjuvant treatments for focal therapy are summarized. A literature search of major databases was performed using the search terms 'focal therapy', 'focal ablation', 'partial ablation', 'targeted ablation', 'image guided therapy' and 'prostate cancer'. Expert commentary: Advanced radiological tools such as multiparametric magnetic resonance imaging (mpMRI), multiparametric ultrasound (mpUS), prostate-specific-membrane-antigen positron emission tomography (PSMA-PET) represent a revolution in the ability to understand cancer function and biology. Advances in ablative technologies now provide a menu of modalities that can be rationalized based on lesion location, size and perhaps in the near future, pre-determined resistance to therapy. However, these need to be carefully studied to establish their safety and efficacy parameters. Adjuvant strategies to enhance focal ablation are under development.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Rev Anticancer Ther

DOI

EISSN

1744-8328

Publication Date

August 2017

Volume

17

Issue

8

Start / End Page

737 / 743

Location

England

Related Subject Headings

  • Ultrasonography, Interventional
  • Prostatic Neoplasms
  • Positron-Emission Tomography
  • Patient Selection
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Magnetic Resonance Imaging
  • Humans
  • Glutamate Carboxypeptidase II
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tay, K. J., Schulman, A. A., Sze, C., Tsivian, E., & Polascik, T. J. (2017). New advances in focal therapy for early stage prostate cancer. Expert Rev Anticancer Ther, 17(8), 737–743. https://doi.org/10.1080/14737140.2017.1345630
Tay, Kae Jack, Ariel A. Schulman, Christina Sze, Efrat Tsivian, and Thomas J. Polascik. “New advances in focal therapy for early stage prostate cancer.Expert Rev Anticancer Ther 17, no. 8 (August 2017): 737–43. https://doi.org/10.1080/14737140.2017.1345630.
Tay KJ, Schulman AA, Sze C, Tsivian E, Polascik TJ. New advances in focal therapy for early stage prostate cancer. Expert Rev Anticancer Ther. 2017 Aug;17(8):737–43.
Tay, Kae Jack, et al. “New advances in focal therapy for early stage prostate cancer.Expert Rev Anticancer Ther, vol. 17, no. 8, Aug. 2017, pp. 737–43. Pubmed, doi:10.1080/14737140.2017.1345630.
Tay KJ, Schulman AA, Sze C, Tsivian E, Polascik TJ. New advances in focal therapy for early stage prostate cancer. Expert Rev Anticancer Ther. 2017 Aug;17(8):737–743.
Journal cover image

Published In

Expert Rev Anticancer Ther

DOI

EISSN

1744-8328

Publication Date

August 2017

Volume

17

Issue

8

Start / End Page

737 / 743

Location

England

Related Subject Headings

  • Ultrasonography, Interventional
  • Prostatic Neoplasms
  • Positron-Emission Tomography
  • Patient Selection
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Magnetic Resonance Imaging
  • Humans
  • Glutamate Carboxypeptidase II